I understand. During our last run on March 29th, I sold twice at $27.78 and at $29.07, based on the 52 week price range estimated by analysts.
But I have become firm in my opinion that we will see demand far in excess of 100K vials. Just in the last week or so, we saw India announce over 400k new cases in just one day. Another country, I think it was Brazil, announced over 300k new cases in just one day.
The best hope for those infected patients is lenzilumab, based on our topline results compared to all other therapeutics.
I realize that it seems incredulous to deduce that we could see over $100B in revenue in the coming 12 months. But that is what I am looking for. We should see further news stemming from the talks Durrant has been having with prospective commercial and governmental purchasers around the world, all of whom have now been advised of our topline results and meeting our primary endpoint, as well as our progress toward an EUA.